Abstract
Gemtuzumab ozogamicin (GO), an anti-CD33 monoclonal antibody conjugated to calicheamicin, is effective as single agent in the treatment of poor risk acute myeloid leukaemia (AML) patients. We treated with GO in combination with cytarabine as continuous perfusion nine elderly AML patients, either untreated (five cases), or with relapsed/refractory disease (four cases). Five patients achieved a complete remission (CR), four were resistant. One patient died while in CR due to CNS haemorrhage, two relapsed and two are still in CR. The median CR duration was 10 months. The median overall survival was 6 months (1-19 months). The most common adverse event was myelosuppression, as expected. No hepatic veno-occlusive disease was recorded. Notably, in four cases we observed a grade III/IV bleeding, including gasto-intestinal bleeding, epistaxis, CNS haemorrhage, and ocular bleeding. Larger prospective studies are now warranted in order to better define the possible role of this regimen in the treatment of elderly AML patients.
References
Mar 17, 2000·Leukemia·J M Rowe
Aug 30, 2002·Leukemia·R A LarsonUNKNOWN Mylotarg Study Group
Nov 27, 2002·Cancer Chemotherapy and Pharmacology·Jorge CortesFrancis J Giles
Dec 24, 2002·Cancer Chemotherapy and Pharmacology·Yesid AlvaradoFrancis J Giles
Mar 11, 2003·Cancer·Apostolia TsimberidouFrancis Giles
Aug 23, 2003·Blood·William J KellDonald W Milligan
Citations
Aug 5, 2008·Cancer Immunology, Immunotherapy : CII·Allison S DrakeMeir Wetzler
May 21, 2013·Annals of Hematology·Marino ClavioMarco Gobbi
Sep 8, 2012·International Journal of Hematology·Yoshikazu ItoTomoki Naoe
May 28, 2013·International Journal of Hematology·Akihiro Takeshita
Mar 30, 2007·Nature Clinical Practice. Oncology·Alejandro D Ricart, Anthony W Tolcher
May 29, 2007·Oncogene·L PaganoG Leone
Mar 2, 2011·Cancer Biotherapy & Radiopharmaceuticals·Robert O Dillman
Aug 4, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·U BrunnbergW E Berdel
Mar 29, 2007·Acta Haematologica·Maria Teresa PirrottaFrancesco Lauria
Jul 12, 2011·Leukemia & Lymphoma·Eunice S WangMeir Wetzler
Nov 14, 2014·Leukemia & Lymphoma·Sylvain P ChantepieOumedaly Reman
Mar 21, 2008·Expert Opinion on Biological Therapy·Roberto Stasi
Aug 4, 2011·Expert Opinion on Biological Therapy·Marie-Luise Hütter, Richard F Schlenk
Mar 25, 2006·Expert Opinion on Pharmacotherapy·Pier Paolo PiccalugaMichele Baccarani
Apr 22, 2009·Cancer Genetics and Cytogenetics·Antoine HarbMeir Wetzler
Apr 28, 2009·Surgical Oncology·Slavica KvolikLjubica Glavas-Obrovac
Aug 12, 2008·Seminars in Oncology·Hervé DombretClaude Gardin
Oct 19, 2007·Cancer Treatment Reviews·Roberto StasiSergio Amadori
Apr 3, 2008·Seminars in Hematology·Deborah Mulford
Nov 6, 2015·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Joshua Seth EatonChristopher J Murphy
Jun 27, 2007·British Journal of Haematology·Marino ClavioMarco Gobbi
Apr 1, 2008·British Journal of Haematology·Jérôme DoyenAntoine Thyss
Feb 15, 2011·British Journal of Haematology·Daniel A PollyeaBruno C Medeiros
Jun 25, 2010·American Journal of Hematology·Iris MiddeldorfStefan Wilop
Jan 1, 2014·American Journal of Hematology·Sylvain PilorgePhilippe Rousselot
Oct 14, 2014·Annals of Hematology·Maya Koren-MichowitzArnon Nagler
Nov 30, 2010·Best Practice & Research. Clinical Haematology·Edward D Ball, H Elizabeth Broome
Apr 8, 2017·Cancer·Prajwal Chaitanya BodduTapan M Kadia
Dec 14, 2004·Leukemia·M L Linenberger
Dec 8, 2007·Onkologie·Beate GleissnerWolfgang E Berdel